DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient

Parainfluenza virus (PIV) may cause life‐threatening pneumonia in lung transplant patients and there are no proven effective therapies. We report the use of inhaled DAS181, a novel sialidase fusion protein, to treat severe PIV type 3 pneumonia in a lung transplant patient. Treatment was well tolerated and associated with improvement in oxygenation and symptoms, along with rapid clearance of PIV. DAS181 should be systematically evaluated for treatment of PIV infection in transplant recipients.

[1]  R. Moss,et al.  Clinical potential of DAS181 for treatment of parainfluenza‐3 infections in transplant recipients , 2012, Transplant infectious disease : an official journal of the Transplantation Society.

[2]  E. Rosenberg,et al.  Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Belperio,et al.  Respiratory Viral Infections in Hematopoietic Stem Cell and Solid Organ Transplant Recipients , 2011, Seminars in respiratory and critical care medicine.

[4]  S. Palmer,et al.  Translating Basic Research into Clinical PracticeBronchiolitis Obliterans Syndrome: The Final Frontier for Lung Transplantation , 2011 .

[5]  L. Aschenbrenner,et al.  A Safety Evaluation of DAS181, a Sialidase Fusion Protein, in Rodents , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[6]  P. Soccal,et al.  Respiratory Viruses in Lung Transplant Recipients: A Critical Review and Pooled Analysis of Clinical Studies , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  L. Aschenbrenner,et al.  A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. , 2010, The Journal of infectious diseases.

[8]  A. Wald,et al.  Respiratory Virus Pneumonia after Hematopoietic Cell Transplantation (HCT): Associations between Viral Load in Bronchoalveolar Lavage Samples, Viral RNA Detection in Serum Samples, and Clinical Outcomes of HCT , 2010, The Journal of infectious diseases.

[9]  D. Pakstis,et al.  A Prospective Molecular Surveillance Study Evaluating the Clinical Impact of Community-Acquired Respiratory Viruses in Lung Transplant Recipients , 2010, Transplantation.

[10]  V. Liu,et al.  A multi‐drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart–lung transplant recipients , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[11]  M. Boeckh,et al.  Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. , 2007, Blood.

[12]  L. Corey,et al.  Comparison of Real-Time PCR Assays with Fluorescent-Antibody Assays for Diagnosis of Respiratory Virus Infections in Children , 2006, Journal of Clinical Microbiology.

[13]  F. Hayden,et al.  Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection , 2006, Antimicrobial Agents and Chemotherapy.

[14]  K. McCurry,et al.  Parainfluenza Virus Infection in Adult Lung Transplant Recipients: An Emergent Clinical Syndrome with Implications on Allograft Function , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  M. Boeckh,et al.  Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. , 2001, Blood.